Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats

International Journal of Pharmaceutics

Volumn 337, Issue 1-2, 2007, Pages 188-193

  Li, Xiuguo ^a,b   Choi, Jun Shik ^a  

^a Chosun University   (South Korea)

^b YANBIAN UNIVERSITY   (China)

Author keywords

Bioavailability; Genistein; Paclitaxel; Pharmacokinetics; Rats

Indexed keywords

GENISTEIN; PACLITAXEL;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 ENZYME SYSTEM; DRUGS, NON-PRESCRIPTION; GENISTEIN; HERB-DRUG INTERACTIONS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; P-GLYCOPROTEIN; PACLITAXEL; PHYTOESTROGENS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 34248512624     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.01.002     Document Type: Article

References (34)

1. Andreeva M., Niedmann P.D., Binder L., Armstrong V.W., Meden H., Binder M., and Oellerich M. A simple and reliable reverse-phase high-performance liquid chromatographic procedure for determination of paclitaxel (taxol) in human serum. Ther. Drug Monit. 19 (1997) 327-332
2. Birt D.F., Hendrich S., and Wang W. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol. Ther. 90 (2001) 157-177
3. Borst P., Evers R., Kool M., and Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92 (2000) 1295-1302
4. Bradshaw D.M., and Arceci R.J. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J. Clin. Oncol. 16 (2000) 3674-3690
5. Castro A.F., and Altenberg G.A. Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein. Biochem. Pharmacol. 53 (1997) 89-93
6. Chan L.M., Lowes S., and Hirst B.H. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci. 21 (2004) 25-51
7. Choi J.S., Kim Y.C., and Jo B.W. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur. J. Pharm. Biopharm. 57 (2004) 313-318
8. Choi J.S., Choi B.C., and Choi K.E. Effect of quercetin on the pharmacokinetics of oral cyclosporine. Am. J. Health-Syst. Pharm. 61 (2004) 1-11
9. Doyle L.A., and Ross D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22 (2003) 7340-7358
10. Gao P., Rush B.D., Pfund W.P., Huang T., Bauer J.M., Morozowich W., Kuo M.S., and Hageman M.J. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J. Pharm. Sci. 92 (2003) 2386-2398
11. Harris J.W., Rahman A., Kim B.R., Guengerich F.P., and Collins J.M. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54 (1994) 4026-4035
12. Higgins C.F. ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol. 8 (1992) 67-113
13. Hu M., Krausz K., Chen J., Ge X., Li J., Gelboin H.L., and Gonzalez F.J. Identification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones. Drug Metab. Dispos. 31 (2003) 924-931
14. Huisman M.T., Chhatta A.A., van Tellingen O., Beijnen J.H., and Schinkel A.H. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int. J. Cancer 116 (2005) 824-829
15. Imai Y., Tsukahara S., Asada S., and Sugimoto Y. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res. 64 (2004) 4346-4352
16. Jager W., Winter O., Halper B., Salamon A., Sartori M., Gajdzik L., Hamilton G., Theyer G., Graf J., and Thalhammer T. Modulation of liver canalicular transport processes by the tyrosine-kinase inhibitor genistein: implications of genistein metabolism in the rat. Hepatology 26 (1997) 1467-1476
17. Kurzer M., and Xu X. Dietary phytoestrogens. Annu. Rev. Nutr. 17 (1997) 353-381
18. Lee S.H., Yoo S.D., and Lee K.H. Rapid and sensitive determination of paclitaxel in mouse plasma by high-performance liquid chromatography. J. Chomatogr. B: Biomed. Sci. Appl. 724 (1999) 357-363
19. Lim S.C., and Choi J.S. Effects of naringin on the pharmacokinetics of intravenous paclitaxel in rats. Biopharm. Drug Dispos. 27 (2006) 443-447
20. Limtrakul P., Khantamat O., and Pintha K. Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J. Chemother. 17 (2005) 86-95
21. Liu Y., and Hu M. Absorption and metabolism of flavonoids in the caco-2 cell culture model and a perused rat intestinal model. Drug Metab. Dispos. 30 (2002) 370-377
22. Meerum Terwogt J.M., Malingre M.M., Beijnen J.H., ten Bokkel Huinink W.W., Rosing H., Koopman F.J., van Tellingen O., Swart M., and Schellens J.H. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin. Cancer Res. 5 (1999) 3379-3384
23. Rahman A., Korzekwa K.R., Grogan J., Gonzalez F.J., and Harris J.W. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 54 (1994) 5543-5546
24. Ren M.Q., Kuhn G., Wegner J., and Chen J. Isoflavones, substances with multi-biological and clinical properties. Eur. J. Nutr. 40 (2001) 135-146
25. Rocci M.L., and Jusko W.J. LAGRAN program for area and moments in pharmacokinetic analysis. Comput. Programs Biomed. 16 (1983) 203-216
26. Rowinsky E.K., Eisenhauer E.A., Chaudhry V., Arbuck S.G., and Donehower R.C. Clinical toxicities encountered with paclitaxel (Taxol). Semin. Oncol. 20 (1993) 1-15
27. Sonnichsen D.S., Liu Q., Schuetz E.G., Schuetz J.D., Pappo A., and Relling M.V. Variability in human cytochrome P450 paclitaxel metabolism. J. Pharmacol. Exp. Ther. 27 (1995) 566-575
28. Sparreboom A., van Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K., Borst P., Nooijen W.J., Bejinen J.W., and van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA 4 (1997) 2031-2035
29. Sutherland L., Ebner T., and Burchell B. The expression of UDP-glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs. Biochem. Pharmacol. 45 (1993) 295-301
30. Turgeon D., Carrier J.S., Levesque E., Hum D.W., and Belanger A. Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 142 (2001) 778-787
31. van Asperen J., van Tellingen O., van der Valk M.A., Rozenhart M., and Beijnen J.H. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin. Cancer Res. 4 (1998) 2293-2297
32. Walle T., Walle U.K., Kuma G.N., and Bhalla K.N. Taxol metabolism and disposition in cancer patients. Drug Metab. Disp. 23 (1995) 506-512
33. Yang C.S., Landau J.M., Huang M.T., and Newmark H.L. Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu. Rev. Nutr. 21 (2001) 381-406
34. Zhang S., Yang X., and Morris M.E. Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm. Res. 21 (2004) 1263-1273